Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Title of 12(b) Security Title of 12(b) Security Carrying Amount Reported Value Measurement [Member] Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Schedule of Fair Value Measurement Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock Common Stock, Value, Issued Employee compensation Employee-related Liabilities, Current Floating Rate Notes Floating Rate Notes [Member] Floating Rate Notes Schedule of Long-Term Notes Schedule of Long-Term Debt Instruments [Table Text Block] Restatement Determination Date Restatement Determination Date Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Derivative Instrument [Axis] Derivative Instrument [Axis] Cash paid for acquisitions, net of cash acquired Other Payments to Acquire Businesses Amendment Flag Amendment Flag Current Liabilities Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Loss Contingencies [Table] Loss Contingencies [Table] Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment Total noncurrent liabilities Liabilities, Noncurrent Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Other equity Other Additional Capital Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Expenditures for long-lived assets Segment Reporting, Long-Lived Asset, Expenditure for Addition Asset Acquisition [Axis] Asset Acquisition [Axis] Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Other intangibles, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Share Repurchase Program [Domain] Share Repurchase Program [Domain] Derivative, notional amount Derivative, Notional Amount Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Investments Noncurrent investments Long-Term Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Loss Contingencies [Line Items] Loss Contingencies [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Schedule of Significant Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Entity Address, City or Town Entity Address, City or Town Estimated fair value as of acquisition date: Business Combination, Contingency Recognized at Acquisition Date, Liability to Asset, Excess (Less), Fair Value [Abstract] Short-term commercial paper borrowings Commercial Paper Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Document Information [Line Items] Document Information [Line Items] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Net product revenue Product [Member] Class of Stock [Axis] Class of Stock [Axis] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Three Acquired Companies Three Acquired Companies [Member] Three Acquired Companies U.S. UNITED STATES Subsequent Event Type [Axis] Subsequent Event Type [Axis] Effect of Change in Accounting Estimate, Type [Domain] Effect of Change in Accounting Estimate, Type [Domain] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Ventyx Ventyx Biosciences, Inc [Member] Ventyx Biosciences, Inc Implementation of New Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Schedule of Segment Reporting Segment Reporting [Table Text Block] Acquisitions Asset Acquisition [Text Block] Trulicity Trulicity [Member] Trulicity [Member] Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Financial Information Regularly Reviewed by the CODM Segment Reporting, Profit (Loss) [Abstract] Acquired in-process research and development (IPR&D) Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill Long-term debt Long-term debt, including current portion Long-Term Debt Document Period End Date Document Period End Date Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Ebglyss Ebglyss [Member] Ebglyss Net Cash Used for Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Equity Equity [Text Block] Costs, expenses, and other: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Expected price of acquisition Business Combination, Price of Acquisition, Expected Position [Axis] Position [Axis] Less: Less Significant Expenses [Abstract] Less Significant Expenses Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee [Line Items] Increase to last-in, first-out cost Inventory, LIFO Reserve Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Name Outstanding Recovery, Individual Name Earnings per share: Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Trading Symbol Trading Symbol Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Geographical [Domain] Geographical [Domain] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Purchases of noncurrent investments Payments to Acquire Other Investments May 2026 May 2026 Issuance Date Debt [Member] May 2026 Issuance Date Debt Retirement Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Scorpion Therapeutics, Inc. (Scorpion) Scorpion Therapeutics Inc [Member] Scorpion Therapeutics Inc Available-for-sale debt securities Debt Securities [Member] Cash Flows from Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Taltz Taltz [Member] Taltz [Member] Other receivables Other Receivables, Net, Current December 2024 Share Repurchase Program December 2024 Share Repurchase Program [Member] December 2024 Share Repurchase Program Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Early-stage Early-Stage [Member] Early-Stage Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial Paper Commercial Paper [Member] Verzenio Verzenio [Member] Verzenio [Member] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Centessa Centessa Pharmaceuticals [Member] Centessa Pharmaceuticals Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Award Timing Predetermined Award Timing Predetermined [Flag] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Effective income tax rates, percentage Effective Income Tax Rate Reconciliation, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] All Executive Categories All Executive Categories [Member] Purchases of common stock Stock Repurchased and Retired During Period, Value Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other oncology Other Oncology [Member] Other Oncology [Member] Schedule of Significant Acquired IPR&D Charges Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation [Table Text Block] Asset Acquisition [Domain] Asset Acquisition [Domain] 0.500% Notes due 2033 0.500% Notes Due 2033 [Member] 0.500% Notes Due 2033 [Member] Acquisition date fair value of consideration Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Late-stage Late-Stage [Member] Late-Stage Segment Information Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Fair value of contingent consideration Business Combination, Consideration Transferred, Liabilities Incurred Business Combination [Line Items] Business Combination [Line Items] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Kelonia Kelonia Therapeutics [Member] Kelonia Therapeutics Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Exercise Price Award Exercise Price Cash Flows from Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Quarterly Report Document Quarterly Report Number of potentially responsible parties Loss Contingency, Number Of Potentially Responsible Parties Loss Contingency, Number Of Potentially Responsible Parties Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Europe Europe [Member] Cash and cash equivalents at January 1 Cash and Cash Equivalents at June 30 Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Repayments of long-term debt Repayments of Long-Term Debt Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity method investments Equity Method Investments Equity Component [Domain] Equity Component [Domain] Business Combination [Table] Business Combination [Table] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Adoption Date Trading Arrangement Adoption Date Cash dividends declared Dividends, Common Stock, Cash Long-term notes Stated interest rate (in percent) Debt Instrument, Interest Rate, Stated Percentage Total equity Beginning balance Ending balance Equity, Attributable to Parent Other–net, (income) expense Nonoperating Income (Expense) Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Insider Trading Policies and Procedures [Line Items] Other financing activities, net Proceeds from (Payment for) Other Financing Activity Costs, expenses, and other Cost Of Sales, Operating Expenses, And Other-net Cost Of Sales, Operating Expenses, And Other-net Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Immunology Immunology [Member] Immunology [Member] Long-term income taxes payable Accrued Income Taxes, Noncurrent Marketing, selling, and administrative Selling, General and Administrative Expense Zepbound Zepbound [Member] Zepbound Business Combination [Domain] Business Combination [Domain] Asset impairment, restructuring, and other special charges Asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Entity Central Index Key Entity Central Index Key Property and equipment, accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other operating activities, net Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net Cash Provided by Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Legal settlement payment Payments for Legal Settlements Other Stockholders' Equity, Other Income Statement [Abstract] Income Statement [Abstract] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Other cardiometabolic health Other Cardiometabolic Health [Member] Other Cardiometabolic Health Designated as accounting hedges Designated as Hedging Instrument [Member] Deferred tax assets Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable rate Debt Instrument, Basis Spread on Variable Rate City Area Code City Area Code Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Document Information [Table] Document Information [Table] All Individuals All Individuals [Member] Dividends paid Payments of Dividends Name Forgone Recovery, Individual Name Other noncurrent liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Contingencies Commitments and Contingencies, Policy [Policy Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Total assets Assets Entity [Domain] Entity [Domain] Interest expense Interest Expense, Nonoperating Reportable Segment Reportable Segment [Member] Reportable Segment Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Other Other Accumulated Comprehensive Income Loss Attributable To Parent [Member] Accumulated Comprehensive Income Loss Other Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] PEO PEO [Member] Purchases of common stock (in shares) Stock Repurchased and Retired During Period, Shares Measurement Basis [Axis] Measurement Basis [Axis] Other noncurrent liabilities Other Liabilities, Noncurrent Goodwill Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Retained Earnings Retained Earnings [Member] Employee benefit trust Common Stock, Shares Held in Employee Trust Cash Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Award Timing Disclosures [Line Items] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Current Reporting Status Entity Current Reporting Status Net Cash Provided by Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Litigation Case Type [Domain] Litigation Case [Domain] Schedule of Short-term and Long-term Classification and Contingent Consideration Liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Cash Flows from Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net of accumulated depreciation of $13,103 (2026) and $12,560 (2025) Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Schedule of Components of Equity Schedule of Stockholders Equity [Table Text Block] Floating Rate Notes Due 2028 Floating Rate Notes Due 2028 [Member] Floating Rate Notes Due 2028 Financial Instruments [Domain] Financial Instruments [Domain] Inventories Inventory Disclosure [Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Fair Value Measurements Using Estimate of Fair Value Measurement [Member] Revenue Revenue from Contract with Customer [Text Block] Prepaid expenses Prepaid Expense, Current Orna Therapeutics, Inc. (Orna) Orna Therapeutics, Inc. [Member] Orna Therapeutics, Inc. Acquired IPR&D Charge Payments for Asset Acquisitions Payments for Asset Acquisitions Other investing activities, net Payment for (Proceeds from) Other Investing Activity Segment Reporting [Table] Segment Reporting [Table] Other current liabilities Business Combination, Contingent Consideration, Liability, Current Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] Acquisitions Business Combination [Text Block] Consideration to be paid Business Combination, Consideration To Be Paid Business Combination, Consideration To Be Paid Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Cash dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished products Inventory, Finished Goods, Gross Short-term investments Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Product and Service [Domain] Product and Service [Domain] 1.700% Notes due 2049 1.700% Notes Due 2049 [Member] 1.700% Notes due 2049 [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Common Stock (no par value) Common Class A [Member] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Recognized in other–net, (income) expense Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Entity Small Business Entity Small Business Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other current liabilities Other Liabilities, Current Other immunology Other Immunology [Member] Other Immunology [Member] Other noncurrent assets Other Assets, Noncurrent Document Type Document Type Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Sell Short [Member] Acquired in-process research and development Acquired in-process research and development Acquired in-process research and development Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff 1.625% Notes due 2043 1.625% Notes Due 2043 [Member] 1.625% Notes Due 2043 Schedule of Change in Accounting Estimate [Table] Change in Accounting Estimate [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Stock repurchase program, remaining authorized amount Share Repurchase Program, Remaining Authorized, Amount Arrangement Duration Trading Arrangement Duration Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Work in process Inventory, Work in Process, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and Contingencies Commitments and Contingencies Revenue Revenue Revenues Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] China CHINA Business Combinations Business Combination [Policy Text Block] Liabilities and Equity Liabilities and Equity [Abstract] Purchases of in-process research and development Payments to Acquire in Process Research and Development Inventories Inventories Inventory, Net All Award Types Award Type [Domain] Rest of world Rest Of World [Member] Rest Of World Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Financial Instruments Fair Value Disclosures [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] PEO Name PEO Name Geographical [Axis] Geographical [Axis] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Other segment items Segment Reporting, Other Segment Item, Amount Cash acquired Cash Acquired from Acquisition Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Donald Zakrowski [Member] Donald Zakrowski Legal Entity [Axis] Legal Entity [Axis] 1.125% Notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 Schedule of Collaborative Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Foreign Currency-Denominated Notes Foreign Currency-Denominated Notes [Member] Foreign Currency-Denominated Notes Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Israel ISRAEL Basis of Presentation and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] 0.625% Notes due 2031 0.625% Notes Due 2031 [Member] 0.625% Notes due 2031 [Member] Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Ajax Therapeutics, Inc. (Ajax) Ajax Therapeutics, Inc. [Member] Ajax Therapeutics, Inc. Purchase Long [Member] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Basic (in dollars per share) Earnings Per Share, Basic Raw materials and supplies Inventory, Raw Materials, Gross Purchases of common stock Payments for Repurchase of Common Stock Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Long-term debt Long-Term Debt, Excluding Current Maturities Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Retained earnings Retained Earnings (Accumulated Deficit) Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Product and Service [Axis] Product and Service [Axis] Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Less: Business Combination, Cash Acquired [Abstract] Business Combination, Cash Acquired Fair Value Measurement [Domain] Fair Value Measurement [Domain] Effect of Change in Accounting Estimate, Type [Axis] Effect of Change in Accounting Estimate, Type [Axis] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Outside U.S. Non-US [Member] 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Derivative Contract [Domain] Derivative Contract [Domain] Sales rebates and discounts Sales Rebates And Discounts Sales Rebates And Discounts Equity Awards Adjustments Equity Awards Adjustments [Member] Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Number of businesses acquired Business Combination, Number of Businesses Acquired Total liabilities and equity Liabilities and Equity Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Short-term borrowings and current maturities of long-term debt Debt, Current Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Floating Rate Notes Due 2029 Floating Rate Notes Due 2029 [Member] Floating Rate Notes Due 2029 Marketable equity securities Equity Securities, FV-NI, Noncurrent Other securities Other Debt Obligations [Member] Name Awards Close in Time to MNPI Disclosures, Individual Name Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Noncurrent Assets Assets, Noncurrent [Abstract] Boehringer Ingelheim Boehringer Ingelheim [Member] Boehringer Ingelheim Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Cost Portion at Other than Fair Value Measurement [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Class of Stock [Domain] Class of Stock [Domain] 1.375% Notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Prepaid taxes Prepaid Taxes Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign Exchange Forward Foreign Exchange Forward [Member] Hedging Designation [Axis] Hedging Designation [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Jardiance Jardiance Jardiance [Member] Jardiance [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Effects of Significant Risk-Management Programs Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Cash paid or to be paid, net of cash acquired Business Combination, Consideration Transferred Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Subsidiary or Equity Method Investee, Sale of Stock [Table] Subsidiary or Equity Method Investee, Sale of Stock [Table] Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Position [Domain] Position [Domain] Company Selected Measure Amount Company Selected Measure Amount Not designated as accounting hedges Not Designated as Hedging Instrument [Member] Roche Roche [Member] Roche [Member] Depreciation and amortization Depreciation, Depletion and Amortization Total (approximates replacement cost) Inventory, Gross Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current Assets Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Income taxes Income Tax Expense (Benefit) Cost of sales Cost of Product and Service Sold Award Timing Method Award Timing Method [Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Other Product and Service, Other [Member] Net increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Contingent consideration Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Number of class action petitions Loss Contingency, Number Of Class Action Petitions Loss Contingency, Number Of Class Action Petitions Research and development Research and Development Expense (Excluding Acquired in Process Cost) Deferred tax liabilities, net Business Combination, Recognized Liability Assumed, Deferred Tax Liability Net income Net income Net income Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Mounjaro Mounjaro [Member] Mounjaro [Member] Cardiometabolic Health Cardiometabolic Health [Member] Cardiometabolic Health Japan JAPAN Recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract]